Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review
出版年份 2022 全文链接
标题
Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review
作者
关键词
-
出版物
PHARMACOECONOMICS
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-02-03
DOI
10.1007/s40273-021-01121-7
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Systemic therapy, survival and end-of-life costs for metastatic triple-negative breast cancer: retrospective SEER-Medicare study of women age ≥65 years
- (2021) Jan Sieluk et al. Future Oncology
- PCN248 Productivity Costs Associated with Disease Recurrence Among Surgically-Treated Patients with Triple-Negative Breast Cancer
- (2021) J. Sieluk et al. VALUE IN HEALTH
- PCN240 Healthcare Resource Utilization Associated with Disease Recurrence Among Surgically-Treated Patients with Triple-Negative Breast Cancer
- (2021) J. Sieluk et al. VALUE IN HEALTH
- Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer
- (2020) S. Adams et al. ANNALS OF ONCOLOGY
- 141P Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple negative breast cancer
- (2020) P. Schmid et al. ANNALS OF ONCOLOGY
- 104P Cost and healthcare resource utilization (HCRU) for patients receiving neoadjuvant therapy for early-stage triple-negative breast cancer (ESTNBC)
- (2020) W.C. Rhodes et al. ANNALS OF ONCOLOGY
- Quality of life among breast cancer survivors with triple negative breast cancer—role of hope, self-efficacy and social support
- (2020) Aomei Shen et al. European Journal of Oncology Nursing
- PCN314 REAL-WORLD PATIENT DEMOGRAPHICS, TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION (HRU) AMONG HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC) PATIENTS WITH BRCA1/2 MUTATIONS (BRCA1/2MUT)
- (2020) R.C. Parikh et al. VALUE IN HEALTH
- PCN308 HEALTH UTILITY IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC TNBC
- (2020) M. Huang et al. VALUE IN HEALTH
- Variability in hospital treatment costs: a time-driven activity-based costing approach for early-stage invasive breast cancer patients
- (2020) Erin Roman et al. BMJ Open
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)†
- (2020) F. Cardoso et al. ANNALS OF ONCOLOGY
- Health-related quality of life in breast cancer patients: review of reviews from 2008 to 2018
- (2020) Parisa Mokhatri-Hesari et al. Health and Quality of Life Outcomes
- Treatment patterns, risk for hospitalization and mortality in older patients with triple negative breast cancer
- (2020) Antonis Valachis et al. Journal of Geriatric Oncology
- A population‐based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple‐negative breast cancer
- (2020) Christine Brezden‐Masley et al. Cancer Medicine
- Early triple-negative breast cancer in women aged ≥65: retrospective study of outcomes, resource use and costs, 2010–2016
- (2020) Jan Sieluk et al. Future Oncology
- Assessing direct costs of treating metastatic triple-negative breast cancer in the USA
- (2020) Karen E Skinner et al. Journal of Comparative Effectiveness Research
- Breast Cancer Treatment
- (2019) Adrienne G. Waks et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Overall survival, costs and healthcare resource use by number of regimens received in elderly patients with newly diagnosed metastatic triple-negative breast cancer
- (2019) Abdalla Aly et al. Future Oncology
- Advocacy for a New Oncology Research Paradigm: The Model of Bevacizumab in Triple-Negative Breast Cancer in a French Cohort Study
- (2019) Benoîte Mery et al. ONCOLOGY
- Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2019) F Cardoso et al. ANNALS OF ONCOLOGY
- PCN58 HUMANISTIC AND ECONOMIC BURDENS OF TRIPLE-NEGATIVE BREAST CANCER: A LITERATURE REVIEW
- (2019) A. Fu et al. VALUE IN HEALTH
- Adjusting for Inflation and Currency Changes Within Health Economic Studies
- (2019) Hugo C. Turner et al. VALUE IN HEALTH
- PCN132 SYSTEMATIC REVIEW OF ECONOMIC BURDEN IN TRIPLE-NEGATIVE BREAST CANCER PATIENTS
- (2019) A. Frederickson et al. VALUE IN HEALTH
- PCN468 SYSTEMATIC REVIEW OF UTILITY ESTIMATES IN TRIPLE-NEGATIVE BREAST CANCER PATIENTS
- (2019) A. Frederickson et al. VALUE IN HEALTH
- Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States
- (2018) Kendra L. Schwartz et al. CANCER
- Outcomes research examining treatments, quality of life and costs in HER2-negative and triple-negative metastatic breast cancer: a systematic literature review
- (2018) Monika Parisi et al. Journal of Comparative Effectiveness Research
- The economic burden of metastatic breast cancer in Spain
- (2018) Begoña Bermejo de las Heras et al. European Journal of Hospital Pharmacy-Science and Practice
- 292OPatient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulation
- (2018) H S Rugo et al. ANNALS OF ONCOLOGY
- Productivity Costs Associated With Breast Cancer Among Survivors Aged 18–44 Years
- (2016) Donatus U. Ekwueme et al. AMERICAN JOURNAL OF PREVENTIVE MEDICINE
- Cancer Associated Medical Spending: US National Data Between 2000 and 2013
- (2016) J Zhuo et al. VALUE IN HEALTH
- Exercise and dietary advice intervention for survivors of triple-negative breast cancer: effects on body fat, physical function, quality of life, and adipokine profile
- (2015) Anne K. Swisher et al. SUPPORTIVE CARE IN CANCER
- Elicitation of Health-Related Quality-of-Life Concepts Associated With Triple-Negative Breast Cancer
- (2015) S Holmstrom et al. VALUE IN HEALTH
- TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases
- (2014) Carey Anders et al. BREAST CANCER RESEARCH AND TREATMENT
- The economic burden of metastatic breast cancer: a U.S. managed care perspective
- (2012) Alberto J. Montero et al. BREAST CANCER RESEARCH AND TREATMENT
- Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry
- (2012) Onur Baser et al. CURRENT MEDICAL RESEARCH AND OPINION
- Economic Burden of Cancer in the United States: Estimates, Projections, and Future Research
- (2011) K. R. Yabroff et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials
- (2008) Kim Cocks et al. EUROPEAN JOURNAL OF CANCER
- Evaluation of Trends in the Cost of Initial Cancer Treatment
- (2008) J. L. Warren et al. JNCI-Journal of the National Cancer Institute
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started